A report from CROI 2018: 1 oral and 4 posters successfully presented
The EPIICAL consortium is pleased to announce 1 oral and 4 poster presentations has been successfully exposed at CROI 2018 in Boston!
CROI 2018 has been held from Sunday 4 March to Wednesday 7 March, in Boston, Massachusetts, at the Hynes Convention Center. CROI is a global model of collaborative science and the premier international venue for bridging basic and clinical investigation to clinical practice in the field of HIV and related viruses.
The EPIICAL Consortium presented results from several study conducted on early treated HIV infected children.
Details of the EPIICAL presentations that took place at CROI 2018 are shown below:
HIV SPECIFIC IGM MEMORY B CELLS DOMINATE IN SERONEGATIVE EARLY-TREATED CHILDREN
Nicola Cotugno, Elena Morrocchi, Ilaria Pepponi, Salvatore Rocca Mark Cameron, Stefano Rinaldi, Silvia Di Cesare, Suresh Pallikkuth, Stefania Bernardi, Nigel Klein, Jintanat Ananworanich, Paolo Rossi, Savita Pahwa, Paolo Palma
This fascinating study investigates whether HIV specific B cells persist in seronegative HIV infected seronegative patients and what are the associated gene signatures after re-encountering the virus.
FACTORS ASSOCIATED WITH HIV DNA LEVELS IN CHILDREN STARTING ART EARLY IN INFANCY
Man Chan, Alfredo Tagarro, Paola Zangari3, Bridget Ferns, Caroline Foster, Anita De Rossi, Eleni Nastouli, M Ángeles Muñoz-Fernández, Diana Gibb1, Paolo Rossi, Carlo Giaquinto, Abdel Babiker, Paolo Palma, Pablo Rojo Conejo
The study focused on the determinants of low viral reservoir in a large cohort of European early treated HIV-1 infected children. Timing of cArt initiation and timing spent on effective ART are main factors associated with low HIV-DNA.
LASTING IMMUNE IMPACTS OF AGE AT START OF ART IN VERTICALLY HIV-INFECTED ADOLESCENTS
Mark Cameron, Stefano Rinaldi, Brian Richardson, Nicola Cotugno, Sion Williams, Suresh Pallikkuth, Lesley R. de Armas, Cheryl Cameron, Rajendra Pahwa, Paolo Palma, Savita Pahwa
Th study explores the impact of early ART on host immune response looking at HIV-specific CD4 T cell functionality and host transcriptome analysis.
TIME TO VIRAL REBOUND AFTER STOPPING ART IN CHILDREN TREATED FROM INFANCY IN CHER
Avy Violari, Man Chan, Kennedy N. Otwombe, Ravindre Panchia, Patrick Jean-Philippe, Diana Gibb, Mark Cotton, Abdel Babiker
The study investigates the time of viral rebound in early treated hiv infected children who interrupt ART in the CHER trial. Results could inform the design of clinical trials involving analytic treatment interruption in paediatric HIV.